Century Therapeutics, Inc. (IPSC): Total Liabilities
$64.77M
As of 2025-12-31
$54.66M
As of 2026-06-30
-29.4%
3-year compound annual growth
+14.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $64.77M | -66.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $191.85M | +9.0% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $175.94M | -4.3% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $183.81M | +346.8% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $41.14M | +23.1% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $33.43M | n/a | 2022-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $64.77M | -66.2% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $1.00B | +15.0% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $306.28M | -10.6% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $58.74M | -71.5% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $215.60M | -0.1% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $242.82M | -34.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $61.05M | +22.6% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $250.22M | +23.9% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $410.94M | +15.6% |
Compare IPSC, IBRX, STRO, ATRA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗